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Multicenter Evaluation of a New
Electrochemiluminescence Immunoassay for Everolimus
Concentrations in Whole Blood
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Michael Vogeser, MD,§ Andre Schuetzenmeister, PhD,¶ Christian Schmiedel,k and Maria Shipkova, MD**
Background: The precise monitoring of everolimus, an immuno-
suppressant drug, is vital for transplant recipients due to its narrow
therapeutic range. This study evaluated the analytical performance of
a new electrochemiluminescence immunoassay (ECLIA) for ever-
olimus concentrations in whole blood.
Methods: Accuracy, imprecision, and sensitivity studies for the
Roche Elecsys everolimus ECLIA were performed at 5 European
laboratories. The ECLIA was compared with liquid chromatography-
tandem mass spectrometry (LC-MS/MS) methods, as well as the
Quantitative Microsphere System everolimus assay.
Results: Everolimus ECLIA accuracies were within the range
100% 6 9%. Coefﬁcients of variation (CVs) across the target range
were #4.8% for repeatability and #8.4% for intermediate impreci-
sion, whereas multisite reproducibility at lower (2.71 mcg/L) and
higher everolimus concentrations (3.0–30.0 mcg/L) resulted in
CVs of #13.7% and #12.4%, respectively. The CV at the assay’s
lower limit of quantiﬁcation without considering bias was excellent,
estimated as #9.3% at 0.5 mcg/L. The weighted Deming regression
analysis, used for comparison of the results obtained by everolimus
ECLIA and by LC-MS/MS methods, yielded a slope of 1.21 [95%
conﬁdence interval (CI): 1.15–1.26], intercept of 0.478 mcg/L (95%
CI: 0.241–0.716), and a Pearson correlation coefﬁcient (r) of 0.91. A
single-site comparison between the ECLIA and the Quantitative
Microsphere System assay revealed a slope of 1.05 (95% CI:
0.917–1.17), intercept of 1.03 mcg/L (95% CI: 0.351–1.70), and
r of 0.91.
Conclusions: Based on these results, the Roche Elecsys ever-
olimus ECLIA can be considered suitable for routine therapeutic
drug monitoring. A positive bias was observed with respect to LC-
MS/MS methods, suggesting that it may be necessary to rebaseline
individual patients when switching from LC-MS/MS to the ECLIA;
however, this must also be considered for any change of method for
everolimus measurement.
Key Words: everolimus, immunoassay, LC-MS/MS, therapeutic
drug monitoring, ECLIA
(Ther Drug Monit 2018;40:59–68)
INTRODUCTION
Everolimus is a synthetic derivative of the mammalian
target of rapamycin inhibitor, sirolimus, with a superior phar-
macokinetic proﬁle.1 It is indicated for all solid transplant recip-
ients.2,3 Therapeutic drug monitoring (TDM) of everolimus is
essential due to its narrow therapeutic index, interindividual and
intraindividual variations in bioavailability and clearance, and
potential for interaction with concomitantly administered drugs.
Furthermore, the need to take everolimus continuously to pre-
vent organ rejection necessitates to obtain precise and accurate
results of the concentration in a patient’s blood.4
Given the good correlation between exposure to ever-
olimus (area under the concentration–time curve) and trough
concentration, measuring trough concentrations is considered
an appropriate strategy for TDM of everolimus in the trans-
plant setting. Recently published guidelines have suggested
that, in general, trough concentrations of everolimus should
be in the therapeutic range of 3–8 mcg/L when used in
combination with other immunosuppressive drugs such as
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calcineurin inhibitors and glucocorticoids, whereas in calci-
neurin inhibitor–free regimens, the therapeutic range should
be 6–10 mcg/L.5,6
Fully validated liquid chromatography-tandem mass
spectrometry (LC-MS/MS) methods, with a lower limit of
quantiﬁcation (LLoQ) close to 1.0 mcg/L, are considered the
methods of choice for monitoring trough concentrations of
everolimus in whole blood.5 However, immunoassays offer
an alternative approach to LC-MS/MS methods with potential
for less complexity, automation, and round-the-clock results.7
To the best of our knowledge, limited published information
is available on the use of these immunoassays in routine
clinical practice.
In this multicenter study, we studied different analytical
performance characteristics (inaccuracy, imprecision, and
LLoQ without considering bias) to evaluate the Elecsys
Everolimus assay, a new electrochemiluminescence immu-
noassay (ECLIA). In addition, a study was performed to test
interchangeability between results obtained by the everolimus
ECLIA and by LC-MS/MS methods, as well as by a QMS
assay.
MATERIALS AND METHODS
Investigational Sites and Instruments
This study was initiated between January and May
2015 at 5 centers in Europe; 2 in Germany (Central Institute
for Laboratory Medicine and Clinical Chemistry, Klinikum-
Stuttgart, Stuttgart, and Hospital of the University of Munich,
Munich), 2 in Belgium (Ghent University Hospital, Ghent,
and Cliniques universitaires St. Luc, Brussels), and 1 in Spain
(Hospital Universitari de Bellvitge, Barcelona). All centers
were experienced in the TDM of immunosuppressive drugs.
The ECLIA evaluation was performed using cobas e 411
instruments at Stuttgart, Munich, Brussels, and Ghent. The
cobas e 601 system was used in Barcelona. All 5 sites used
LC-MS/MS method for routine measurement of everolimus
concentrations. The Ghent site also used an Indiko Plus ana-
lyzer (Thermo Scientiﬁc, Waltham, MA) and the QMS ever-
olimus assay (Thermo Scientiﬁc) for everolimus method
comparison experiments.
Ethical Approval
Independent ethics committee approval was obtained
before study initiation at each of the 5 centers (Central Institute
for Laboratory Medicine and Clinical Chemistry, Klinikum-
Stuttgart; Hospital of the University of Munich; Ghent
University Hospital; Cliniques universitaires St. Luc; and
Hospital Universitari de Bellvitge) and the study was con-
ducted according to the Declaration of Helsinki (as amended in
Tokyo, Venice, and Hong Kong) and International Council for
Harmonisation of Technical Requirements for Pharmaceuticals
for Human Use Good Clinical Practice guidelines.
Samples
For the inaccuracy experiments, commercial proﬁ-
ciency testing samples from the International Proﬁciency
Testing (IPT) Immunosuppressant Scheme (LGC Standards,
Bury, Lancashire, United Kingdom) were used.8
PreciControl Everolimus (PC E 1–3; Roche R&D,
Penzberg, Germany) from Roche Diagnostics (Roche Diag-
nostics GmbH, Rotkreuz, Switzerland) at concentrations of
2.71 mcg/L (PC E L1), 9.84 mcg/L (PC E L2), and 20.1
mcg/L (PC E L3) were used to estimate imprecision. Also,
5 human sample pools (HSP; whole blood) within the con-
centration range of 0.5–30 mcg/L (HSP2–6) were used.
To estimate the LLoQ without considering bias of the
ECLIA, the following 11 spiked HSP samples (whole blood)
that covered an everolimus target concentration range from
0.2 to 2.0 mcg/L were used: HSP7, 2.0 mcg/L; HSP8,
1.8 mcg/L; HSP9, 1.6 mcg/L; HSP10, 1.4 mcg/L; HSP11,
1.2 mcg/L; HSP12, 1.0 mcg/L; HSP14, 0.8 mcg/L; HSP15,
0.4 mcg/L; HSP16, 0.3 mcg/L; and HSP17, 0.2 mcg/L.
Anonymized, residual whole blood samples, originally
collected by a single venipuncture into plasma tubes with
ethylenediaminetetraacetic acid-K3, from patients (native sam-
ples) under everolimus therapy who had received either a kidney,
liver, or heart transplant, were used for the interchangeability
studies (method comparison experiments). In addition, leftover
anonymized samples from the Medizinische Hochschule
Hannover were used to reach the targeted sample numbers for
each transplant type in Ghent and Munich. Samples, if tested
within 5 days of collection, were allowed to be stored at room
temperature (18–258C) or at 2–88C for up to 1 week. Where
longer storage was necessary, samples were frozen at between
215 and2258C, or ideally at2808C, if available. Whole blood
aliquots for method comparisons were used within 24 hours and
then stored at 2–88C between measurements.
Procedures of Assays
The Elecsys Everolimus ECLIA (Roche Diagnostics),
which uses the principle of electrochemiluminescence for
measurement and is for use on the cobas e analyzers (Roche
Diagnostics), was performed according to instructions from
the manufacturer.9 Brieﬂy, the material to be measured (cal-
ibration, internal quality control [QC], and whole blood sam-
ples) are equilibrated to room temperature (18–258C) and
mixed, without vortexing, immediately before use. The
material to be measured (300 mL) is combined with 300 mL
of Elecsys ISD Sample Pretreatment Reagent (Roche Diag-
nostics) in a microcentrifuge tube, capped, and vortexed for
at least 10 seconds. The samples are then centrifuged for
4 minutes at $10,000g. The supernatant is decanted into an
appropriate vial and capped until loading onto the system.
Only 35 mL of supernatant is aspirated by the analyzer. The
total assay duration is 18 minutes.
The Elecsys Everolimus ECLIA is calibrated using the
Roche Elecsys Everolimus CalSet (Roche Diagnostics) with
2 concentrations (0.6 and 23.7 mcg/L). Calibrators were
reconstituted according to the manufacturer’s instructions10
and stored in 300 mL aliquots at 2–88C or below –158C.
Calibrators were prepared for measurement as described
above and used within 30 minutes of preparation. Calibration
was performed once per reagent lot and as required for
maintaining QC values within speciﬁed limits (instrument
speciﬁcations). The lot calibration stability period is 28 days.
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The QC material, PreciControl Everolimus, at 3 concentration
levels, was provided by Roche Diagnostics. The QC samples
were prepared and stored using the same methodology as for
the calibrators. Once prepared, QC samples were measured
within 30 minutes. Each instrument run was validated by
measuring the QC material and comparing control results
with speciﬁed ranges before patient sample material was
measured.
The measuring range of the everolimus ECLIA is
0.5–30 mcg/L (deﬁned by the LLoQ without considering bias
and the maximum of the master curve).9 Values below the LLoQ
without considering bias are reported as ,0.5 mcg/L and those
above the measuring range are reported as .30 mcg/L.
The QMS Everolimus assay (Thermo Fisher Scientiﬁc)
is a homogeneous particle-enhanced turbidimetric immuno-
assay with a measuring range of 2.0–20.0 mcg/L (according
to the assay documentation, with the lower value based on the
lower limit of quantitation).11 The lower limit of detection for
the QMS assay has been reported as 0.7 mcg/L.12 The QMS
Everolimus assay procedures were performed according to
the manufacturer’s instructions on a Thermo Fisher Scientiﬁc
Indiko Plus analyzer.11 This included the use of the value-
assigned calibrators and controls from the manufacturer to
minimize the positive bias from the QMS assay against LC-
MS/MS.5,11–15
Each investigational site performed LC-MS/MS based
on their protocols developed and routinely used at the site.
Table 1 summarizes LC-MS/MS methods used by each
laboratory.
Inaccuracy
The ECLIA was used to measure PC E (n = 3) and IPT
(n = 6) samples on either the cobas e 411 or cobas e 601
analyzers. Samples were also measured using LC-MS/MS
methods at all centers, and with the QMS assay at the center
in Ghent.
Calibration was performed on the LC-MS/MS as a part
of each run, as described above for the ECLIA. Samples were
divided into 3 aliquots and measured in a single run with
3 replicates for each sample. Inaccuracy, expressed as relative
mean recovery (%) using the target value as conventional
value, was calculated for each sample in each center. LC-MS/
MS target values for the IPT samples were provided by LGC
Standards and based on the mean values assigned by the
proﬁciency testing program. The results from these pro-
ﬁciency tests were used as the reference values in this
evaluation.
Imprecision
The repeatability (within-run) and intermediate (within-
lab) imprecision experiments according to the CLSI EP05-A3
guideline were performed at 4 sites (Stuttgart, Brussels,
Ghent, and Barcelona).16 A total of 84 aliquots from each
of the 3 PC E controls and the 5 HSP samples were tested
over a 21-day period using a model with 2 runs per day and
2 replicates per run. Samples were randomized for each run.
Reproducibility was assessed at 3 centers (Stuttgart,
Ghent, and Munich) according to CLSI EP05-A3 guide-
lines.16 Site-to-site, lot-to-lot, and day-to-day variance
components were estimated as well as their sum (reproduc-
ibility). Each site used 2 different reagent lots, and samples
were measured over 5 days, with 5 aliquots per sample
(crossed-nested design), resulting in 150 measurements
from each sample. The same 3 PC E samples and 5 HSP
samples used to measure repeatability and intermediate
imprecision were also used for the reproducibility experi-
ments. Protocol-deﬁned acceptance criteria for repeatability
were # 60.24 mcg/L (SD) for everolimus concentrations in
the range 0.5–3 mcg/L and coefﬁcient of variation (CV) of
#8% for concentrations .3–30 mcg/L. For intermediate
imprecision, the acceptance criteria were # 6 0.360 mcg/L
(SD) for levels in the range of 0.5–3 mcg/L and CV of #12%
for concentrations .3–30 mcg/L. The acceptance criteria for
reproducibility were # 60.54 mcg/L (SD) for everolimus in
the range of 0.5–3 mcg/L and #18% (CV) for concentrations
.3–30 mcg/L. The acceptance criteria were determined based
on discussions with laboratory users.
Lower Limit of Quantification
The LLoQ without considering bias of the everolimus
ECLIA was determined by assessing the lowest concentration
that could be estimated with a CV #20%. The ECLIA LLoQ
without considering bias was assessed at the Munich site
using the cobas e 411 analyzer. Eleven HSP samples
(described previously, 1 aliquot per sample) were analyzed
in each run; 2 runs were performed per day for 5 days in total.
Interchangeability Studies (Method
Comparisons)
Method comparisons were performed to assess whether
the new Elecsys Everolimus ECLIA was interchangeable with
the LC-MS/MS methods and the QMS Everolimus assay.
Method comparison experiments with LC-MS/MS methods
were performed at all centers and additionally with the QMS
assay at the center in Ghent. Each study center used
anonymized residual samples and aimed to test native
samples from at least 60 kidney, 60 liver, and 60 heart
transplant recipients. In total, 200 native samples were tested
in Barcelona, 70 in Brussels, 153 in Ghent, 177 in Munich,
and 184 in Stuttgart using different LC-MS/MS methods and
the ECLIA. In addition, in Ghent, 151 native samples were
processed using the QMS assay and using the ECLIA.
Statistical Analysis
The everolimus ECLIA test results were captured
directly from a laptop computer attached to the cobas e
411/c 6000 analyzer using the Windows-based Computer-
Aided Evaluation (WinCAEv) program, version 2.2.2, CFR
21 Part 11–compliant electronic data capture software that
had been developed and validated for Roche-sponsored stud-
ies.17 Reference assay output was entered ofﬂine into
WinCAEv at each center and source data veriﬁed from ana-
lyzer printouts.
For imprecision, the mean, SD, and CV were estimated
using statistical software R (The R Foundation) with the
variance component analysis package version 1.2.1.18 For
reproducibility experiments, a variance component analysis
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TABLE 1. LC-MS/MS Methods Used at the 5 Investigational Sites
Investigational
Center
LC/MS
Manufacturer/
Model
Method
Working
Range
(mcg/L)
Sample
Preparation
(Extraction)
Internal
Standard Calibrators
Chromatographic
Separation
Interday
Imprecision
Values (CV%)
Barcelona Waters Acquity
UPLC/
Waters TQD
1.42–49.5 PPT with
ZnSO4 and
acetonitrile
[13C2D4]-
everolimus
RECIPE
ClinCal
(whole blood
calibrator set
level 0–6)
Column: Acquity
UPLC BEHTM
C18 reverse-
phase column
(30 · 2.1 mm)
(Waters, Milford,
MA); Mobile
phase: A: 0.1%
(v/v) formic acid
and 2 mmol/L
ammonium
acetate in water,
B: 0.1% (v/v)
formic acid and
2 mmol/L
ammonium
acetate in
methanol;
Elution Mode:
nonlinear
gradient.
Temperature:
558C; Injected
sample volume:
20 mL; Run time:
2.5 min
#8.7
Brussels Agilent 6460 +
HPLC
Agilent 1290
1.2–45.0 ZnSO4
precipitation
with
methanol
everolimus d4 RECIPE
ClinCal
(whole blood
calibrator set
level 0–6)
Column: Agilent
Zorbax C18, 4.6
· 50 mm
#3.89
Ghent Waters Acquity
UPLC/
Waters TQD
0.5–30.0 PPT with
ZnSO4 and
acetone
followed by
liquid–liquid
extraction
with
chlorobutane
32-dimethoxy-
rapamycin
(Wyeth #
AY-24668-1)
Chromsystems
whole blood
calibrator
Column: Waters
MassTrak TDM
C18 2.1 ·
10 mm; Mobile
Phase: 2 mmol/L
ammonium
acetate +0.1%
formic acid in
water and
methanol;
Elution mode:
gradient
50%–100%;
Temperature:
558C; Injected
sample volume:
20 mL; Run time:
1.8 min
#7.9
Munich Waters Quattro
Ultima Pt
0.6–50 PPT with
MeOH/
ZnSO4 (4:1)
followed by
on-line solid
phase
extraction
(Oasis HLB
trapping
column)
[13C2D4]-
everolimus
Chromsystems
6PLUS1
Column: Waters
Sunﬁre C18
column. Ninety
percent MeOH/
10% 0.1%
formic acid,
isocratic elution
#9.5
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was performed to breakdown the overall variance into single
factors contributing to the total observable variability (multi-
lot reproducibility), which corresponded to the sum of all
individual variance components (site-to-site, lot-to-lot, day-
to-day, and repeatability). Imprecision results and outliers
were handled in compliance with the CLSI EP05-A3 guide-
lines.16 For the repeatability and intermediate imprecision
assessments, it was permitted to reject at most 2 results
because of an outlier. This rule was applied for each impre-
cision sample and each 21-day experiment and did not
include runs eliminated due to failed QC or handling errors
(wrong sample, missing values, etc). In these cases, the whole
day was excluded and replaced by another. For reproducibil-
ity experiments, it was permitted to reject at most 1 result
because of an outlier, and this was applied for each precision
sample and each 5-day experiment.
Method comparison evaluation was performed with
WinMC 2.0 using exported data from WinCAEv and was
compliant with the CLSI EP09-A3 guidelines.19 Weighted
Deming regression analysis was used for method compari-
sons with each center’s LC-MS/MS method and with the
QMS Everolimus assay. Pearson’s correlation coefﬁcient (r)
was calculated for each comparison. To gain further informa-
tion on method comparability, Bland–Altman difference plots
were performed.20 The relative bias at clinically relevant
medical decision points was determined for the everolimus
ECLIA versus LC-MS/MS method comparisons. The medical
decision points were deﬁned as the therapeutic range for
everolimus, which was between 3 and 8 mcg/L.
RESULTS
Inaccuracy
With respect to the 3 PC E samples, at concentrations of
2.71, 9.84, and 20.1 mcg/L, all everolimus ECLIA results
were within a mean % recovery range of 91.0%–105.4%
(Table 2); the median bias across the analytical sites was
21.4% to +2.6%. The mean % recovery range for the
LC-MS/MS was 81.1%–130.3% (median bias, 20.8% to
+10.4%), whereas, the recovery ranges relative to target val-
ues were markedly lower for the QMS Everolimus assay
(57.6%–72.5%); however, this was performed at 1 site only.
This ﬁnding is most likely explained by standardization of the
assay against patient samples, which usually show high levels
of metabolite cross-reactivity that cannot be observed in
spiked QC materials.
With respect to the spiked IPT samples, the everolimus
ECLIA results generally fell within the mean % recovery
range of 78.5%–122.8% with 1 exception (IPT 73A). All
LC-MS/MS methods were within the mean % recovery range
of 90.9%–128.4%. Differences in recovery rates were not
unexpected because each center used different calibrators
(2 centers used RECIPE calibrators and 3 centers used Chrom-
systems calibrators), chromatographic conditions, and mass-
spectrometer setup. Recovery rates using the QMS everolimus
assay relative to target were markedly lower (range from
54.9% to 87.2%), a ﬁnding that mirrored the results observed
using the PC E samples.
TABLE 1. (Continued ) LC-MS/MS Methods Used at the 5 Investigational Sites
Investigational
Center
LC/MS
Manufacturer/
Model
Method
Working
Range
(mcg/L)
Sample
Preparation
(Extraction)
Internal
Standard Calibrators
Chromatographic
Separation
Interday
Imprecision
Values (CV%)
Stuttgart Waters H-Class
Acquity/
Xevo-TQD
0.6–50 PPT with
ZnSO4 and
acetonitrile
everolimus d4 Chromsystems
6PLUS1
Column: MZ-
Analysentechnik
MZ Aqua Perfect
C18 150 ·
3.0 mm, 5 mm;
Mobile phase: A:
0.1% (v/v)
formic acid and 2
mmol/L
ammonium
acetate in water,
B: 0.1% (v/v)
formic acid and 2
mmol/L
ammonium
acetate in
methanol;
Elution Mode:
nonlinear
gradient;
Temperature:
658C; Injected
sample volume:
10 mL; Run time:
5.0 min
#7.10
PPT, protein precipitation.
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Imprecision
Repeatability and Intermediate Imprecision
With respect to repeatability estimated from pooling all
4 sites, the SDs of the lower everolimus concentration control
samples (PC E L1 and HSP 2; 0.5–3.0 mcg/L) were 0.142 and
0.108 mcg/L, respectively, and CVs were all #4.8% for the
higher concentration samples and were thus within the prede-
ﬁned acceptance criteria (Table 3). Intermediate imprecision
SDs were #0.263 mcg/L for the lower concentration samples,
and the CVs were#8.4% for the rest of the processed samples,
which again were within the predeﬁned acceptance criteria.
Reproducibility
Lot-to-lot and site-to-site variability SDs were all
#0.15 mcg/L for sample concentrations in the range
0.5–3 mcg/L (HSP2 samples) and #7.0% CV for samples
TABLE 2. Mean Measured Values (mcg/L) and the Mean Recovery Rate Relative to Target Value (%) in PC E and IPT Samples
Samples (Target Concentration)
Investigational Center
Ghent Stuttgart Munich
ECLIA LC-MS/MS QMS ECLIA LC-MS/MS ECLIA LC-MS/MS
Mean Concentration Measured, mcg/L (Mean % Recovery Relative to Target Value)
PC E L1 (2.71 mcg/L) 2.47 (91.3) 2.87 (105.8) 1.57 (57.8) 2.73 (100.7) 2.69 (99.2) 2.72 (100.3) 2.43 (89.8)
PC E L2 (9.84 mcg/L) 9.06 (92.0) 11.07 (112.5) 5.67 (57.6) 9.77 (99.3) 9.88 (100.4) 9.74 (99.0) 9.30 (94.5)
PC E L3 (20.1 mcg/L) 19.76 (98.3) 24.50 (121.9) 14.57 (72.5) 20.79 (103.4) 22.00 (109.5) 21.18 (105.4) 20.87 (103.8)
IPT 73A (1.1 mcg/L) 1.21 (110.3) 1.00 (90.9) N/a* 1.80 (163.4) 1.21 (109.7) 1.54 (139.7) 1.23 (112.1)
IPT 73C (3.0 mcg/L) 3.08 (102.7) 3.07 (102.2) 1.65 (54.9)† 3.68 (122.8) 3.18 (105.9) 3.03 (101.0) 3.27 (108.9)
IPT 76A (5.0 mcg/L) 4.74 (94.7) 5.50 (110.0) 4.36 (87.2) 6.07 (121.3) 5.42 (108.5) 5.30 (105.9) 5.60 (112.0)
IPT 76C (10.2 mcg/L) 9.35 (91.6) 11.27 (110.5) 7.86 (77.0) 11.26 (110.4) 10.42 (102.1) 9.91 (97.2) 11.47 (112.4)
IPT 77C (10.0 mcg/L) 9.29 (92.9) 11.53 (115.3) 8.26 (82.6) 11.28 (112.8) 10.32 (103.2) 9.44 (94.4) 11.27 (112.7)
IPT 78A (14.4 mcg/L) 12.13 (84.3) 14.80 (102.8) 11.92 (82.8) 14.76 (102.5) 15.16 (105.3) 11.31 (78.5) 16.13 (112.0)
Samples (Target Concentration)
Investigational Center All Sites
Brussels Barcelona
Median Measured Concentration
(Median % Recovery) Across All Sites
ECLIA LC-MS/MS ECLIA LC-MS/MS cobas e 411 LC-MS/MS
Mean Concentration Measured, mcg/L (Mean % Recovery Relative to
Target Value)
PC E L1 (2.71 mcg/L) 2.49 (91.8) 2.45 (90.2) 2.72 (100.4) 3.40 (125.5) 2.72 (100.3) 2.69 (99.2)
PC E L2 (9.84 mcg/L) 9.71 (98.6) 7.98 (81.1) 9.32 (94.7) 11.77 (119.6) 9.71 (98.6) 9.88 (110.4)
PC E L3 (20.1 mcg/L) 20.63 (102.6) 20.37 (101.4) 18.29 (91.0) 26.2 (130.3) 20.64 (102.6) 22.0 (109.5)
IPT 73A (1.1 mcg/L) 1.67 (152.1) 1.35 (122.7) 1.47 (133.6) 1.30 (118.2) 1.54 (139.7) 1.23 (112.1)
IPT 73C (3.0 mcg/L) 2.91 (96.9) 3.12 (104.1) 3.08 (102.8) 3.57 (118.9) 3.08 (102.7) 3.18 (105.9)
IPT 76A (5.0 mcg/L) 5.42 (108.3) 5.42 (108.5) 5.13 (102.5) 6.10 (122.0) 5.30 (105.9) 5.50 (110.0)
IPT 76C (10.2 mcg/L) 10.01 (98.2) 11.02 (108.1) 9.15 (89.7) 13.10 (128.4) 9.91 (97.2) 11.27 (110.5)
IPT 77C (10.0 mcg/L) 9.78 (97.8) 11.61 (116.1) 10.01 (100.1) 12.37 (123.7) 9.78 (97.8) 11.53 (115.3)
IPT 78A (14.4 mcg/L) 13.50 (93.8) 16.03 (111.3) 13.31 (92.4) 18.20 (126.4) 13.31 (92.4) 16.03 (111.3)
*3/3 of these results were lower than the measuring range of the assay (all were ,1.5 mcg/L).
†1/3 results were lower than the measuring range (all were ,1.5 mcg/L); therefore, this value was calculated based on 2/3 results.
TABLE 3. Repeatability and Intermediate Imprecision of the Everolimus ECLIA Obtained in 4 Centers (Pooled Data)
Sample (Target Concentration)
mcg/L
Mean Concentration, mcg/L
(Measured Range)
Repeatability, SD/CV
(Measured Range)
Intermediate Imprecision, SD/CV
(Measured Range)
PC E L1 (2.71) 2.78 (2.55–3.18) 0.14 mcg/L (0.09–0.17) 0.26 mcg/L (0.22–0.36)
PC E L2 (9.84) 9.91 (9.34–10.59) 3.1% (2.5–3.5) 5.6% (4.8–6.5)
PC E L3 (20.1) 20.95 (20.03–21.20) 3.3% (2.6–3.8) 5.9% (4.4–6.9)
HSP2 (0.5–3) 2.39 (2.14–2.75) 0.11 mcg/L (0.08–0.12) 0.23 mcg/L (0.16–0.32)
HSP3 (3–8) 5.60 (5.24–6.20) 4.6% (3.8–5.6) 8.4% (5.7–11.3)
HSP4 (8–16) 11.97 (11.38–12.73) 4.0% (3.1–4.6) 5.9% (5.5–6.4)
HSP5 (16–24) 20.54 (19.83–21.38) 4.8% (2.3–7.9) 7.9% (4.5–12.2)
HSP6 (24–30) 24.89 (24.82–25.27) 4.1% (3.3–5.1) 7.4% (4.9–8.3)
Verstraete et al Ther Drug Monit  Volume 40, Number 1, February 2018
64 Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of
Therapeutic Drug Monitoring and Clinical Toxicology.
of concentrations .3–30 mcg/L (PC E L1–3 and HSP3–6
samples) (Table 4). These results were based on 150 meas-
urements of each sample at the 3 centers and were within
predeﬁned acceptance criteria. This held true when outliers,
deﬁned according to CLSI EP05-A3 criteria, were also
included in the analyses.
In terms of the multi-lot reproducibility for the samples
with low everolimus concentrations, CV for the PC E L1
sample was 13.7% at a measured mean concentration of
3.06 mcg/L. The SD for the HSP2 sample was 0.338 mcg/L at
a measured mean concentration of 2.60 mcg/L. The CVs for
the higher concentration samples (PC E L2–3 and HSP3–6
samples) were all #12.4%.
LLoQ Without Bias
Figure 1 shows a plot of CVs determined from a single
measurement of 8 evaluable pools (3 of the 11 samples fell
below 0.3 mcg/L everolimus and so were not included) over
10 runs in 5 days (2 runs per day) at each concentration. The
CV at the LLoQ without considering bias (0.5 mcg/L) was
9.3%.
Interchangeability Studies (Method
Comparisons)
Weighted Deming regression analysis of the everolimus
ECLIA results versus LC-MS/MS results, based on ethyl-
enediaminetetraacetic acid whole blood samples from all 784
transplant patients, yielded a slope of 1.21 [95% conﬁdence
interval (CI): 1.15–1.26], intercept of 0.478 mcg/L (95% CI:
0.241–0.716), and Pearson’s r of 0.91 (Fig. 2A). Pooled data
sets for each organ type (kidney, liver, and heart) were com-
parable in that the slope did not differ signiﬁcantly between
samples from different organs. Data from liver transplant pa-
tients showed a wider scatter than data from kidney or heart
transplant patients, possibly due to impaired hepatic metabo-
lism of everolimus in liver transplant patients resulting in
a potentially more complex, heterogeneous, and pronounced
metabolite proﬁle. For completeness, the method comparison
results at the individual sites are shown in Supplemental
Digital Content 1 (see Supplementary Figure 1, http://
links.lww.com/TDM/A226).
Bland–Altman analysis revealed that the mean bias for
whole blood samples measured on the ECLIA versus LC-MS/
MS methods was 1.46 mcg/L (62 SD 20.98 to +3.91;
Fig. 2B). The estimated relative bias at the medical
decision points for everolimus (ie, at the lower and upper
limits of the therapeutic range, 3–8 mcg/L) were 36.5%
(95% CI: 33.6%–39.3%) at 3 mcg/L and 26.5% (95% CI:
23.4%–29.4%) at 8 mcg/L.
Comparison of the results obtained by everolimus
ECLIA and by the QMS everolimus assay yielded a slope
of 1.05 (95% CI: 0.917–1.17) (Fig. 2C), intercept of
1.03 mcg/L (95% CI: 0.351–1.70), and Pearson’s r of 0.91.
The mean bias calculated by Bland–Altman analysis was
1.23 mcg/L (62 SD 21.37 to +3.82; Fig. 2D).
DISCUSSION
This multicenter evaluation of the analytical perfor-
mance characteristics of the everolimus ECLIA showed that
this new immunoassay meets the performance criteria deﬁned
in recently published guidelines for routine TDM of ever-
olimus in patients undergoing solid organ transplantation,
with respect to method imprecision and inaccuracy.5
TABLE 4. Reproducibility of the Everolimus ECLIA at 3 Centers Based on 150 Measurements of Each Sample
Sample (Target Concentration)
mcg/L
Mean Measured Conc.,
mcg/L Lot-To-Lot (SD/CV) Site-To-Site (SD/CV)
Multi-Lot Reproducibility†
(SD/CV)
PC E L1 (2.71) 3.06 ,0.1% 7.0% 13.7%
PC E L2 (9.84) 10.22 ,0.1% (,0.1%)* 5.6% 9.7%
PC E L3 (20.1) 21.27 ,0.1% (,0.1%)* 5.6% 9.8%
HSP2 (0.5–3.0) 2.60 0.00 mcg/L 0.15 mcg/L 0.34 mcg/L
HSP3 (3.0–8.0) 5.85 ,0.1% 6.6% 12.4%
HSP4 (8.0–16.0) 12.22 ,0.1% (,0.1%)* 4.8% (4.5%)* 8.7% (8.8%)*
HSP5 (16.0–24.0) 20.94 ,0.1% (,0.1%)* 4.8% (5.1%)* 8.9% (9.2%)*
HSP6 (24.0–30.0) 25.25 ,0.1% (,0.1%)* 5.8% 10%
*Initial value with outlier.
†Multi-lot reproducibility, total observable variability that corresponds to the sum of all individual variance components (site-to-site, lot-to-lot, and day-to-day repeatability).
FIGURE 1. Determination of LLoQ without considering bias of
the everolimus ECLIA, using HSP samples across a target
concentration range of 0.2–2.0 mcg/L. LLoQ without consid-
ering bias was defined as 0.5 mcg/L.
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According to international recommendations, a CV
below 5% (at middle and high therapeutic concentrations)
and better than 10% (for concentrations at the lower end of
the therapeutic range) should be achieved with assays for
immunosuppressive drugs.15,21 Results from this study
showed that the everolimus ECLIA met these criteria. At least
95% of all measured data for repeatability and intermediate
imprecision were within internationally recognized accep-
tance criteria; intermediate imprecision found at subtherapeu-
tic concentrations of ;2.8 mcg/L was ,6% (the therapeutic
range of everolimus is estimated to be 3.0–8.0 mcg/L),6 high-
lighting the suitability of this assay for clinical practice.
The ECLIA had an LLoQ without considering bias of
0.5 mcg/L with a CV of 9.3%. This emphasizes that the
measurement range of the everolimus ECLIA is appropriate
for the span of drug concentrations observed in samples
typically seen in routine clinical practice, as well as for
extended pharmacokinetic investigations.
Procedures with a high detection capability are needed
for TDM of everolimus because of the relatively low whole
blood concentrations obtained with the doses of everolimus
used for immunosuppression.13 Despite their complexity,
LC-MS/MS methods have been widely adopted because they
possess the requisite blend of performance characteristics
including capability of detection, selectivity, precision, and
accuracy. Recently published guidelines suggest that, at pres-
ent, a fully validated LC-MS/MS method should be consid-
ered the preferred method for measuring trough
concentrations of everolimus in whole blood.5,13 Therefore,
each center’s LC-MS/MS method was used as the reference
FIGURE 2. Weighted Deming regression and Bland–Altman plots of the everolimus ECLIA versus LC-MS/MS methods (A, B) and
versus QMS everolimus assay (C, D), using native samples from solid organ transplant patients.
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method in this study for comparative purposes. Weighted
Deming regression analysis of the everolimus ECLIA results,
in comparison with those obtained using LC-MS/MS meth-
ods, generally demonstrated a linear correlation between the 2
test procedures when based on pooled results from all 5 cen-
ters. To meet recent consensus guidelines for the selective
measurement of everolimus concentrations, the linear regres-
sion slope should be within 610% of the theoretical value of
1.0 together with a linear regression intercept that is not sta-
tistically signiﬁcantly different from zero and a standard error
of the estimate (Syx) #10% of the average of the therapeutic
concentrations.5,13 Our results, using native samples, suggest
that these tighter criteria were not met because the slope for
the pooled data exceeded 1.1. The magnitude of the slope
deviation was consistent with that reported in a recent
single-center method comparison study of the Elecsys ever-
olimus assay (cobas e 411 analyzer; Roche Diagnostics
GmbH, Rotkreuz, Switzerland) and LC-MS/MS methodol-
ogy, where the slope was 1.131 (Passing–Bablok regres-
sion).22 Immunoassays can be affected by cross-reactivity,
especially from metabolites of the parent drug, which can
lead to overestimation of drug concentrations and potential
for dosing inaccuracies.23 The higher slope value shown in
our study was likely due to cross-reactivity of metabolites.
This slope/deviation bias suggests that individual patients
should be rebaselined when switching from LC-MS/MS
method to the ECLIA. However, rebaselining is also
required when switching from LC-MS/MS to a different LC-
MS/MS method due to lack of interchangeability between the
methods. Redeﬁnition of the target ranges for everolimus
would also be necessary.5,6,22
The QMS everolimus assay is one of the more recently
approved tests for quantitation of everolimus concentrations
in whole blood in organ-transplanted patients.12,24 In our
comparison between the everolimus ECLIA results and the
QMS everolimus assay results, on samples from solid organ
transplant recipients, good agreement was observed between
the 2 assays with respect to the slope value and Pearson
correlation coefﬁcient. However, there was also an intercept
of 1.03, meaning bias; therefore, interchangeability was not
demonstrated. It should be noted that method comparisons
between the QMS assay and the LC-MS/MS method revealed
a signiﬁcant positive bias with the QMS everolimus assay,
such that 69% of whole blood samples from organ transplant
recipients were at supratherapeutic concentrations.11,12,14,15
This overestimation of everolimus concentrations could result
in inadequate dose adjustments in clinical practice, as pre-
viously reported.15,22 Therefore, to minimize the bias between
the QMS everolimus assay and the LC-MS/MS method, the
QMS everolimus calibrators and QCs from the manufacturer
are initially value assigned using a representative set of clin-
ical trough samples from renal and liver transplant patients
with traceability to LC-MS/MS values, which are 70% of
their gravimetric concentrations.5,11,13 Again, the present
ﬁndings are in agreement with those from a recent single-
center study, which demonstrated that results generated using
the Elecsys everolimus assay (cobas e 411 analyzer), QMS
everolimus assay (Dimension Xpand Plus analyzer; Siemens
Healthcare GmbH, Erlangen, Germany), and LC-MS/MS
methodology were not consistent regarding their diagnostic
value.22 Compared with the earlier study,22 this study is novel
in several respects, including its multicenter design; the eval-
uation of the accuracy, imprecision (repeatability, intermedi-
ate imprecision, and reproducibility), and LLoQ without
considering bias of the Elecsys assay; demonstration of the
interchangeability between results obtained using the evero-
limus ECLIA and by 5 different LC-MS/MS methods (based
on the analysis of 784 native samples in total); and inter-
changeability between results obtained using the everolimus
ECLIA and QMS assays applied to the Thermo Fisher Sci-
entiﬁc Indiko Plus analyzer.
Although the LC-MS/MS method is considered the
current method of choice for monitoring trough concentra-
tions of everolimus in solid organ transplant recipients,
the everolimus ECLIA offers practical advantages over
LC-MS/MS methods, especially with respect to ease of
performance and time taken to perform analyses. The use of
ECLIA technology does not impose any limitations on the
development of new assays. For example, the technology
allows for the development of a wide range of assay types,
ranging from small molecules (eg, steroid hormones) to very
large proteins (eg, thyroglobulin), and also offers additional
advantages over existing methods, including a rapid turn-
around time and long reagent stability.25,26
CONCLUSIONS
In this large multicenter evaluation, the everolimus
ECLIA demonstrated good precision, accuracy, and sensitiv-
ity for TDM of everolimus in solid organ transplant recipients
and generally agreed with LC-MS/MS methods. However, in
some centers, there was evidence of slope deviation/bias in
the method comparison experiments, suggesting that it may
be necessary to rebaseline individual patients when switching
from LC-MS/MS methodology to ensure proper patient
handling.
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